Lipocine (LPCN) Q2 2025 earnings summary

Executive summary

• Focused on oral drug delivery for CNS, liver, and hormone disorders, with a pipeline including LPCN 1154 (postpartum depression), LPCN 2401 (obesity/GLP-1 adjunct), LPCN 2101 (epilepsy), and others.

• Initiated pivotal Phase 3 trial for LPCN 1154 in postpartum depression, with topline results expected Q2 2026 and NDA submission planned for mid-2026.

• Advanced LPCN 2401 for obesity management, with Phase 2 study in GLP-1 eligible patients to begin Q3 2025.

• Commercialization of TLANDO (oral testosterone) through multiple licensing agreements in the US, Canada, South Korea, GCC, and Brazil, with milestone and royalty revenue potential.

• Seeking partners for further development and commercialization of pipeline assets.

Financial highlights

• Q2 2025 revenue was $623K, up from $90K in Q2 2024, driven by $500K license revenue and $123K royalty revenue.

• Net loss for Q2 2025 was $2.2M ($0.41/share), improved from $3.1M ($0.57/share) in Q2 2024; six-month net loss was $4.1M ($0.76/share) vs. net income of $445K ($0.10/share) in prior year, which included a $7.5M license payment.

• R&D expenses rose to $2.1M in Q2 2025, mainly due to LPCN 2401 study initiation; G&A expenses fell to $0.9M.

• Cash, cash equivalents, and marketable securities totaled $17.9M as of June 30, 2025, down from $21.6M at year-end 2024.

Outlook and guidance

• Current capital resources expected to fund operations through at least August 2026, including ongoing clinical trials.

• Topline results for LPCN 1154 Phase 3 trial expected Q2 2026; NDA submission planned for mid-2026.

• Additional capital will be needed for expanded development or if milestones are not met; potential sources include equity, debt, or out-licensing.